CN111568793B - Acne removing gel and preparation method thereof - Google Patents
Acne removing gel and preparation method thereof Download PDFInfo
- Publication number
- CN111568793B CN111568793B CN202010312554.0A CN202010312554A CN111568793B CN 111568793 B CN111568793 B CN 111568793B CN 202010312554 A CN202010312554 A CN 202010312554A CN 111568793 B CN111568793 B CN 111568793B
- Authority
- CN
- China
- Prior art keywords
- solution
- propylene glycol
- poloxamer
- salicylic acid
- acne
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 23
- 206010000496 acne Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 238000001879 gelation Methods 0.000 title description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 51
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 40
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229920001992 poloxamer 407 Polymers 0.000 claims abstract description 24
- 229940044476 poloxamer 407 Drugs 0.000 claims abstract description 24
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 20
- 239000000243 solution Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- WLOMWJGRCLMZPW-UHFFFAOYSA-N 2-hydroxybenzoic acid;propane-1,2-diol Chemical compound CC(O)CO.OC(=O)C1=CC=CC=C1O WLOMWJGRCLMZPW-UHFFFAOYSA-N 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229940062251 propylene glycol salicylate Drugs 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 11
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides an acne-removing gel and a preparation method thereof, belonging to the field of cosmetics. The acne-removing gel is prepared by dissolving salicylic acid in propylene glycol and adding poloxamer 407; the mass ratio of the propylene glycol to the poloxamer 407 is 1:1-2. The invention also discloses a preparation method of the acne-removing gel. The salicylic acid is dissolved by the propylene glycol, so that the irritation of the product to skin and pox is reduced, and the utilization rate of an effect substance is improved.
Description
Technical Field
The invention relates to the field of cosmetics, and particularly relates to an acne-removing gel and a preparation method thereof.
Background
Salicylic acid is a fat-soluble organic acid, and can dissolve the constituent substances between horny layers to cause the horny layer to fall off, so that the horny layer accumulated too thickly can be removed to promote metabolism. The salicylic acid acts on hair follicle wall cells, can help to remove blocked hair follicles, correct abnormal cell shedding, and has an auxiliary effect on pox caused by pore obstruction. Salicylic acid is therefore commonly used in anti-acne products. Salicylic acid is only slightly soluble in water and easily soluble in ethanol, diethyl ether, chloroform, etc., so many products are often added with alcohol as a solvent for salicylic acid. However, a large part of the acne skin belongs to sensitive skin, and the addition of acne causes the destruction of the cuticle, so that adverse reactions such as pain, wound healing inhibition and the like are easily caused after the acne skin contacts alcohol. In addition, the alcohol acne removing product causes the dissolved salicylic acid to precipitate and become a solid crystal state again along with the volatilization of alcohol, thereby influencing the skin absorption and reducing the utilization rate of the efficacy materials. Ethanol toxicology data-rabbit eye: 500mg, heavy stimulation; rabbit percutaneous open stimulation test: 15mg/24 h, moderate stimulation.
Disclosure of Invention
The first purpose of the invention is to provide an acne removing gel.
The second purpose of the invention is to provide a preparation method of the acne removing gel.
In order to achieve the purpose, the acne removing gel provided by the invention is prepared by dissolving salicylic acid in propylene glycol and then adding poloxamer 407; wherein the mass ratio of the propylene glycol to the poloxamer 407 is 1:1-2.
The invention also provides a preparation method of the acne removing gel, which comprises the following specific steps:
s1, dissolving 10g of poloxamer 407 in 50-100g of deionized water at room temperature, standing and refrigerating;
s2, adding 1g of salicylic acid into 5-10g of propylene glycol, and heating to 45-55 ℃ for dissolution;
and S3, taking out the completely dissolved poloxamer 407 aqueous solution, slowly pouring the dissolved propylene glycol salicylate solution into the solution, and stirring the solution at room temperature until the solution is uniform to obtain the poloxamer.
Wherein the mass ratio of the poloxamer 407 to the deionized water in the step S1 is 1:5-10.
Wherein the refrigerating temperature in the step S1 is 5 ℃.
Wherein the refrigerating time in the step S1 is 8-12h.
Wherein the mass ratio of the salicylic acid to the propylene glycol in the step S2 is 1:5-10.
Propylene glycol belongs to a low-irritation and low-toxicity solvent, and rats are injected intravenously and intraperitoneally with LD 50 7000-8000mg/kg, oral LD 50 It was 2800mg/kg. Poloxamer 407 is used as a stabilizer for salicylic acid, which forms micelles in water, increasing the surface solubility of salicylic acid; poloxamer 407 has good compatibility with skin, can be used as an absorption enhancer, and can increase the absorption and utilization of salicylic acid by skin; poloxamer 407 as a high molecular material for preparing the temperature-sensitive in-situ gel has the advantages of good spreadability, large mucous membrane coverage, long detention time, simple preparation, convenient use and the like.
The invention has the beneficial effects that:
according to the invention, the propylene glycol is used as a solvent, so that the stimulation of the use of alcohol to the skin in the traditional process is reduced, and the propylene glycol and the poloxamer 407 in a specific proportion can effectively improve the acne removing effect of the acne removing gel. The invention has simple process, good product effect and better use value.
Detailed Description
In order to more clearly and completely describe the technical scheme of the invention, the invention is further described in detail by the specific embodiments, and it should be understood that the specific embodiments described herein are only used for explaining the invention, and are not used for limiting the invention, and various changes can be made within the scope defined by the claims of the invention.
Example 1
Adding 10g of poloxamer 407 into 100g of deionized water at room temperature, standing in a refrigerating chamber at 5 ℃ for 8h; 1g of salicylic acid is added to 10g of propylene glycol; heating to 45 ℃ to dissolve; and taking out the completely dissolved poloxamer 407 aqueous solution, slowly pouring the dissolved propylene glycol salicylate solution into the solution, and stirring the solution at room temperature until the solution is uniform.
Example 2
Adding 10g of poloxamer 407 into 50g of deionized water at room temperature, standing in a refrigerating chamber at 5 ℃ for 10 hours; 1g of salicylic acid was added to 7.5g of propylene glycol; heating to 50 ℃ to dissolve; and taking out the completely dissolved poloxamer 407 aqueous solution, slowly pouring the dissolved propylene glycol salicylate solution into the solution, and stirring the solution at room temperature until the solution is uniform.
Example 3
Adding 10g of poloxamer 407 into 50-100g of deionized water at room temperature, standing in a refrigerating chamber at 5 ℃ for 12 hours; 1g of salicylic acid is added to 5g of propylene glycol; heating to 55 ℃ for dissolution; and taking out the completely dissolved poloxamer 407 aqueous solution, slowly pouring the dissolved propylene glycol salicylate solution into the solution, and stirring the solution at room temperature until the solution is uniform.
Comparative example 1
Adding 10g of poloxamer 407 into 100g of deionized water at room temperature, standing in a refrigerating chamber at 5 ℃ for 8h; adding 1g of salicylic acid to 15g of propylene glycol; heating to 45 ℃ to dissolve; and taking out the completely dissolved poloxamer 407 aqueous solution, slowly pouring the dissolved propylene glycol salicylate solution into the solution, and stirring the solution at room temperature until the solution is uniform.
Comparative example 2
Adding 5g of poloxamer 407 into 100g of deionized water at room temperature, standing in a refrigerating chamber at 5 ℃ for 8h; 1g of salicylic acid is added to 10g of propylene glycol; heating to 45 ℃ to dissolve; and taking out the completely dissolved poloxamer 407 aqueous solution, slowly pouring the dissolved propylene glycol salicylate solution into the solution, and stirring the solution at room temperature until the solution is uniform.
Performance evaluation:
100 acne patients were selected for the trial, with male and female halves, ages 20-30 years, and a mean age of 24 years. The average was divided into 5 groups (half of men and women), and the acne removing gels prepared in examples and comparative examples were used for experience. The composition is administered once a day for 2 weeks, and then the therapeutic effect is evaluated. The evaluation was divided into: 1. and (3) curing: the skin loss is reduced by more than 90 percent, and no new rash symptoms appear; 2. the effect is shown: the skin loss is reduced by more than 60 percent, and the symptoms are obviously relieved; 3. the method has the following advantages: the skin loss is reduced by more than 30 percent, and the symptoms are improved; 4. and (4) invalidation: the skin loss resolved below 30% with no significant change in symptoms. The evaluation results are shown in table 1.
TABLE 1
Examples | Cure of disease | Show effect | Is effective | Invalidation | Total effective rate |
Example 1 | 1 | 12 | 6 | 1 | 95% |
Example 2 | 3 | 13 | 4 | 0 | 100% |
Example 3 | 2 | 10 | 6 | 2 | 90% |
Comparative example 1 | 0 | 3 | 12 | 5 | 75% |
Comparative example 2 | 0 | 4 | 10 | 6 | 70% |
The performance evaluation effect of the table 1 shows that the acne removing gel provided by the invention has a good acne removing effect, and the effect of the comparative example shows that when the ratio of the propylene glycol to the poloxamer 407 exceeds 1:1-2, the acne removing effect is poor, and no curing effect is achieved.
Finally, it should be emphasized that the above-described preferred embodiments of the present invention are merely examples of implementations, and it should be understood that various changes and modifications may be made by those skilled in the art, and any changes, equivalents, improvements and the like, which fall within the spirit and principle of the present invention, should be included in the scope of the present invention.
Claims (1)
1. The acne removing gel is characterized in that the preparation method of the acne removing gel comprises the following steps: adding 10g of poloxamer 407 into 50g of deionized water at room temperature, standing in a refrigerating chamber at 5 ℃ for 10 hours; 1g of salicylic acid was added to 7.5g of propylene glycol; heating to 50 ℃ to dissolve; and taking out the completely dissolved poloxamer 407 aqueous solution, slowly pouring the dissolved propylene glycol salicylate solution into the solution, and stirring the solution at room temperature until the solution is uniform.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010312554.0A CN111568793B (en) | 2020-04-20 | 2020-04-20 | Acne removing gel and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010312554.0A CN111568793B (en) | 2020-04-20 | 2020-04-20 | Acne removing gel and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111568793A CN111568793A (en) | 2020-08-25 |
CN111568793B true CN111568793B (en) | 2023-04-07 |
Family
ID=72089993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010312554.0A Active CN111568793B (en) | 2020-04-20 | 2020-04-20 | Acne removing gel and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111568793B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107108905A (en) * | 2014-11-20 | 2017-08-29 | 博任达生化科技有限公司 | Water-soluble supramolecular complex |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2585575B1 (en) * | 1985-08-01 | 1989-03-03 | Pf Medicament | PHARMACEUTICAL COMPOSITIONS WITH KERATOLYTIC ACTIVITY IN GEL FORM COMPRISING HYDROALCOHOLIC SALICYLIC ACID |
US20160279162A1 (en) * | 2013-11-18 | 2016-09-29 | Polyremedy, Inc. | Micelle-based delivery of dermal therapeutic materials |
CN109771333A (en) * | 2019-01-18 | 2019-05-21 | 德之馨(上海)有限公司 | Salicylic acid solubilising slow releasing composition and its preparation method and application |
CN110840834B (en) * | 2019-12-09 | 2021-08-10 | 山东百奥生物医药有限公司 | Preparation process of 30% concentration liquid slow-release salicylic acid |
-
2020
- 2020-04-20 CN CN202010312554.0A patent/CN111568793B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107108905A (en) * | 2014-11-20 | 2017-08-29 | 博任达生化科技有限公司 | Water-soluble supramolecular complex |
Non-Patent Citations (1)
Title |
---|
刘文.泊洛沙姆.《药用高分子材料学》.中国中医药出版社,2017,第161-162页. * |
Also Published As
Publication number | Publication date |
---|---|
CN111568793A (en) | 2020-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1473300B1 (en) | Pharmaceutical composition for the treatment of psoriasis and other skin diseases | |
AU557858B2 (en) | Preparation and method for the treatment of acne | |
CN113975280B (en) | Pharmaceutical composition containing tofacitinib pharmaceutically acceptable salt, preparation and application | |
WO2022178983A1 (en) | External preparation of natural drug, preparation method, and application thereof | |
WO2017219839A1 (en) | Anti-acne traditional chinese medicinal ointment and preparation method therefor | |
CN111568793B (en) | Acne removing gel and preparation method thereof | |
ES2909243T3 (en) | Salvia haenkei extract as an active agent in re-epithelialization and tissue healing processes | |
EP2854784B1 (en) | Method for treating skin inflammatory diseases | |
JP2001502346A (en) | Zinc salt of conjugated linoleic acid for the treatment of skin diseases | |
CN110840834B (en) | Preparation process of 30% concentration liquid slow-release salicylic acid | |
KR100530843B1 (en) | Anti-inflammatory composition containing paecilomyces extract and cordyceps extracts as effective composition | |
JPS63501868A (en) | Skin composition with keratolytic and anti-inflammatory activity | |
CN103520232B (en) | A kind of preparation method of gel | |
JP2860550B2 (en) | Acute skin inflammation treatment | |
CN114404333A (en) | Facial cleansing mousse with acne removing effect and preparation method and application thereof | |
CN110664668A (en) | Acne-removing skin-care gel containing water-soluble cannabidiol and preparation method thereof | |
KR101982837B1 (en) | Melting method for sucralfate, liquid cosmetics involving sucralfate and method for producing thereof | |
EP4081190B1 (en) | Composition for suppositories for the treatment of the prostatic diseases | |
JP4717970B2 (en) | Antiplasmin | |
JP2518704B2 (en) | Zinc cysteate, method for producing the same, and use in medicine and cosmetics | |
KR102312654B1 (en) | Anti-inflammaging composition | |
CN117503758A (en) | A pharmaceutical composition for topical treatment of psoriasis and its preparation method | |
CN117860636A (en) | Composition containing lemon extract and application of composition in preparation of product with acne removing effect | |
CN118078892A (en) | External medicine for treating skin diseases and preparation method thereof | |
CN114504581A (en) | Compound triamcinolone acetonide salicylic acid liniment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |